Document is current

Article History

Received: 14 December 2021

Accepted: 6 July 2022

First Online: 17 August 2022

Declarations

:

: Receipt of signed and dated informed consent is a requirement for inclusion in the trial. A trial investigator or delegate will obtain informed, freely given, written consent from each subject via a consent form, after confirming that the subject understands the content of the form. This trial will be initiated only after all required legal documentation has been reviewed and approved by the responsible IRB/IEC and CA according to national and international regulations. The same applies for the implementation of changes introduced by amendments.

: All authors consent to the publication of this article. The Boehringer Ingelheim transparency and publication policy can be found on the following web page: . The consent documents are available from the corresponding author on request.

: VC declares that he is an employee of Janssen R&D LLC, but that this work was performed prior to Janssen employment and is not endorsed by Janssen; at the time of project initiation, he was an employee of Boehringer Ingelheim. QDN declares funding from Boehringer Ingelheim, Genentech, Gilead, Regeneron and Santen and consulting for AsclepiX, Bayer, Regeneron and Santen. YS declares financial support from Boehringer Ingelheim. AG and EP declare that they are employees of Boehringer Ingelheim.